Albumin Market to Grow at a CAGR of 6.9% over 2025 to 2032; Growing Burden of Life-threatening Diseases to Drive Market Growth

The global albumin market size was valued at USD 6.80 billion in 2024. The market is projected to grow from USD 7.23 billion in 2025 to USD 11.54 billion by 2032, exhibiting a CAGR of 6.9% during the forecast period. Fortune Business Insights™ presents this information in its report titled “Albumin Market Size, Share & Industry Analysis, By Product (Human Serum Albumin, Recombinant Albumin, and Bovine Serum Albumin), By Application (Therapeutics, Diagnostics, and Research), By End-user (Hospitals & Clinics, Pharmaceutical & Biotechnology Industry, and Research Institutes), and Regional Forecast, 2025-2032”.

Albumin, a liver-produced protein, plays a crucial role in nutrient transport and fluid regulation. Types include recombinant, bovine serum, and human serum. It is vital in drug delivery, wound healing, and managing conditions such as hypoalbuminemia. Life-threatening diseases such as liver infections are boosting product demand, with market players investing in novel solutions. Shilpa Medicare's trial of sRbumin-recombinant human albumin highlights efforts to meet growing needs, supporting market expansion.

The COVID-19 pandemic in 2020 significantly boosted the market due to its use in R&D activities, including vaccine stabilization. Research, such as the NCBI study (April 2022), highlighted the importance of albumin injections in COVID-19 patients with low albumin levels to prevent severe complications, driving demand. Although plasma shortages slowed growth in 2021, the market rebounded in 2022 with improved supply and product launches. 

Bio Products Laboratory Ltd. Launch of ALBUMINEX 5% (human albumin) Solution

In May 2020, Bio Products Laboratory Ltd. announced the U.S. launch of ALBUMINEX 5% (human albumin) solution for injection and ALBUMINEX 25% solution for injection to treat hypovolemia, ascites, and hypoalbuminemia. The launch of this injection is expected to boost the product portfolio of the company, enhancing its market position.

Increased Presence of Recombinant Albumin in Diverse Application Areas to Fuel Market Progress

Recombinant albumin's superior purity and hydrophobic properties enhance its effectiveness in treating low albumin levels, drug delivery, and restoring blood volume. Its growing use in critical conditions such as dialysis, surgeries, and liver failure underscores its market demand. Moreover, key players are strengthening their portfolios through partnerships, such as Albumedix's collaboration with FUJIFILM Wako in March 2021 for recombinant albumin supply in Asia. Additionally, innovations such as InVitria's blood-free albumin products improve patient safety and treatment efficacy, fueling market growth.

However, the security of approved albumin-based therapeutic options restricts its commercialization and adoption, deterring albumin market growth.

Industry Players Focus on Developing Innovative Therapeutics to Expand Their Portfolios

Major players such as CSL Behring and Grifols, S.A., dominate the market in 2024, driven by their focus on developing innovative therapeutics. For example, CSL Behring partnered with Baheal Medical in March 2021 to improve access to human albumin products in China. Additionally, companies such as AG and Grifols are seeking regulatory approvals to expand their portfolios, further boosting market growth.

List of Key Players Mentioned in the Report:

• CSL Behring (CSL), (U.S.)
• Kedrion S.p.A. (Italy)
• Takeda Pharmaceutical Company Limited (Japan)
• Lazuline Bio (India)
• InVitria (U.S.)
• Biorbyt Ltd. (U.K.)
• Grifols, S.A. (Spain)
• Octapharma AG (Switzerland)
• Albumin Bioscience (U.S.)
• Aspira Chemical (U.S.)
• ALBUMEDIX (Sartorius AG) (Germany)
• Cyagen Biosciences (U.S.)
• Merck KGaA (Germany)
• Thermo Fisher Scientific Inc. (U.S.)

Key Industry Development

• June 2024: Dyadic International, Inc, in partnership with Proliant Health and Biologicals (PHB) agreed to develop and commercialize advanced products.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/albumin-market-102637

Further Report Findings

• The Asia Pacific region held the dominant position in the market. Biotest AG's launch of human albumin sales in China in June 2020 for treating severe diseases, such as burns and chronic conditions, highlights the region’s growing market potential.
• The European market is set for considerable growth, fueled by key players’ strategies such as establishing plasma fractionation centers, strategic partnerships, and the introduction of new products to enhance their portfolios.
• By product, in 2024, the human serum segment secured the key albumin market share. Government initiatives, such as the CHM's June 2023 approval of domestically sourced plasma in the U.K., and increasing hypoalbuminemia drug sales are fueling the segment's growth in the albumin market.
• In 2024, the hospital & clinics segment held the largest market share, fueled by the increasing use of product in critical care. NCBI (2021) highlighted its frequent use for treating hypovolemia, sepsis, and hypotension in nephrology and surgical departments.

Table of Segmentation